A dual GLP-1 and GIP receptor agonist used for type 2 diabetes and obesity, enhancing insulin secretion, suppressing glucagon, and promoting weight loss.
Shukla. Alpana P AP; Dunn. Julia P JP; Gomez Valderas. Elisa E; Fraseur Brumm. Julia J; Karanikas. C...
In a 72‑week study of people with obesity (but no diabetes), tirzepatide helped them lose more weight than semaglutide and also boosted their overall sense of health, especially in areas like general health and physical functioning. While both drugs improved physical health scores, mental health scores stayed about the same. The biggest quality‑of‑life gains were seen in participants who lost the most weight or started with poorer physical function.
In a 52‑week trial, people with fatty liver disease (MASH) who took tirzepatide lost a lot of weight, lowered their blood sugar, and reduced liver fat, which was linked to real improvements in liver health. The bigger the weight loss and the better the blood sugar control, the more likely the liver disease got better.
AbuAlrob. Majd A MA; Hussein. Abdullah A; Abdellatif. Rand R; Itbaisha. Adham A; Zammar. Khaled K; M...
A big study looked at adults who have both epilepsy and type 2 diabetes and started them on GLP‑1 drugs like tirzepatide. Compared to other diabetes meds, those on GLP‑1 drugs had fewer seizure relapses, fewer hospital stays, and lower death rates. The results are promising but still need confirmation in future trials.
Masulli. Maria M; Tack. Jan J; Esposito. Giuseppe G; Sarnelli. Giovanni G
Tirzepatide is a powerful drug that can lower blood sugar, help you lose weight, and protect your heart, but many people get stomach upset like nausea, bloating, and feeling full too quickly. These gut problems can be temporary, but some folks keep feeling bad and may stop the drug early. The study says you should plan ahead by checking who might be at risk, starting with a low dose, raising it slowly, and getting help from doctors, diet experts, or gut specialists to keep the benefits while easing the stomach issues.
Fahim. Sally A SA; Attia. Yasmin M YM; Messiha. Albeir A; Nabawy. Ashrakat Y AY; Refaat. Fady F; El-...
The review compares two weight‑loss drugs, semaglutide (a GLP‑1 only agonist) and tirzepatide (both GLP‑1 and GIP agonist). Both cause typical gut side effects, but tirzepatide appears to have fewer overall issues and may actually help bone health and protect the kidneys, making it a potentially safer choice for long‑term use.
Henney. Alex E AE; Riley. David R DR; Anson. Matthew M; Azmi. Shazli S; Alam. Uazman U; Cuthbertson....
In a big real‑world study, people with type‑2 diabetes who took tirzepatide had about half the chance of serious liver problems over two years compared to those on older diabetes drugs, while semaglutide helped a bit and liraglutide didn’t help at all. This suggests tirzepatide may protect the liver in diabetics with fatty‑liver disease.
Hoffmann. Karolina K; Michalak. Michał M; Rizzo. Manfredi M; Maggio. Viviana V; Paczkowska. An...
Tirzepatide, taken once a week at 5, 10, or 15 mg, leads to big drops in weight (about 10–15 kg) and improves blood sugar control in people with type‑2 diabetes or obesity. The higher the dose, the bigger the benefit. It appears safer than insulin for serious side‑effects and low blood sugar, but it can cause more stomach upset.
Savage. Matthew J MJ; Goldney. Jonathan J; Slater. Tommy T; Sarkar. Priscilla P; Sargeant. Jack A JA...
Early‑onset type 2 diabetes is a fast‑growing, high‑risk group that suffers from more complications and mental health issues. The review says there are very few studies focused on these younger adults, but the ones that exist show that tirzepatide, bariatric surgery, and intensive lifestyle changes can dramatically improve weight, blood sugar, and overall health. Technology‑based tools and education look promising but still need solid trial data.
In a 3‑month study of 60 people with type 2 diabetes, tirzepatide lowered blood sugar (HbA1c) and body weight while also changing how participants ate. Their overall eating‑behavior scores improved, and they felt the diet was more worthwhile, even though they reported the diet felt a bit more burdensome.
Kettner. Jordyn J; Donnelly. Elizabeth E; Maes. Marina L ML
Tirzepatide, a new weight‑loss drug, can slow stomach emptying, which may make birth‑control pills work less well, so people should consider using a non‑oral method or timing the pill differently. The drug’s weight‑loss effects can also boost fertility, but there isn’t enough safety data for use during pregnancy or while nursing, so caution is advised.
Roddy. Kevin L KL; Greenwald. Matthew R MR; Hollman. Nicholas N; Dorand. Madisen F MF; Richards. Jes...
A small study of kidney‑transplant candidates showed that the weight‑loss drug tirzepatide helped most people (about 78%) drop enough weight to qualify for transplant, doing almost as well as bariatric surgery. Semaglutide worked less well, and combining surgery with a GLP‑1 drug gave the best results. The findings suggest tirzepatide could be a non‑surgical way to lose weight before a transplant, but the evidence is still early.
Witaszek. Tomasz T; Biesiada. Aleksander A; Iskra-Trifunović. Joanna J; Babicki. Mateusz M; Ma...
The review shows that most people taking tirzepatide (and similar drugs) for weight loss get stomach problems like nausea and diarrhea. These side effects happen because the drugs change how the stomach moves and affect appetite hormones. The good news is that you can reduce them by starting with a low dose, increasing slowly, eating the right foods, and using supportive meds if needed.
A big review of 21 trials (about 100,000 people) shows that drugs in the GLP‑1 family—including tirzepatide—cut overall death, heart‑related death and major heart events, even in people without diabetes. They also lower serious problems like heart attacks, kidney failure and infections, but they do raise the chance of stomach upset and gallbladder issues. The benefits and side‑effects differ a bit between each drug, so you can pick the one that fits your goals and tolerance.
Barrett. Tyson S TS; Hafermann. Juliane O JO; Richards. Shannon S; LeJeune. Keith K; Eid. George M G...
A big US study found that, for people with severe obesity, having bariatric surgery (like sleeve gastrectomy or gastric bypass) leads to about three times more weight loss than using GLP‑1 drugs such as tirzepatide, and it actually costs less over two years because the drug group keeps paying high pharmacy bills.
Tuccinardi. Dario D; Masi. Davide D; Watanabe. Mikiko M; Zanghi Buffi. Valeria V; De Domenico. Franc...
The review says tirzepatide, a new dual GIP/GLP‑1 drug, can help people who are overweight or obese not just lose weight but also improve heart health, kidney function, liver disease, and even symptoms of heart failure, regardless of whether they have diabetes. It works best when you match the drug to your specific health profile (like age, heart disease risk, or liver issues) and combine it with good diet, exercise, and protein intake.
In a study of people with obesity or overweight, staying on tirzepatide kept them losing weight and feeling better in daily life, while stopping the drug caused them to regain weight and feel worse. The benefits were bigger for those who lost more weight or started with physical limitations.
Betensky. Daniel J DJ; Smith. Karen C KC; Katz. Jeffrey N JN; Yang. Catherine C; Hunter. David J DJ;...
Tirzepide, a weight‑loss drug, not only helps people drop pounds but also eases knee‑joint pain in those who are obese and have osteoarthritis. The study shows it gives more health benefit for less money than the similar drug semaglutide and is cheaper than surgery, making it a practical, cost‑effective option for everyday use.
Franco. Juan Va JV; Guo. Yang Y; Varela. Lucia B LB; Aqra. Zakariya Z; Alhalahla. Murad M; Medina Ro...
Tirzepatide, a once‑weekly injection, can shave off about 15% of body weight over a year compared with placebo, and many more people reach at least a 5% loss. It does raise mild, non‑serious side effects, while serious harms and heart benefits are still uncertain. Quality of life and death rates don’t change much.
Hong. Alexander T AT; Lin. Forest F; Luu. Ivan Y IY; Shin. Laura L; Han. Sukgu M SM; Armstrong. Davi...
In people with peripheral artery disease (PAD) and type‑2 diabetes, drugs that activate the GLP‑1 receptor—especially semaglutide and tirzepatide—cut the risk of major leg amputations, need for leg re‑vascularisation, and overall death compared with other diabetes meds like SGLT2 inhibitors or DPP‑4 inhibitors.
Barazzoni. Rocco R; Monami. Matteo M; Buscemi. Silvio S; Busetto. Luca L; De Luca. Maurizio M; Navar...
In people with mild to moderate obesity (BMI 30‑39.9), the drug tirzepatide works about as well as the most common weight‑loss surgeries and better than other medicines. For very severe obesity (BMI > 40), surgery still beats the drug. This means tirzepatide can be a practical, non‑surgical first‑line option for many who want big weight loss without the risks of an operation.